Dr Davidson Ateh, CEO, discusses BioMoti’s Oncojan™ intracellular drug delivery technology for cancer treatment with Tom Mulligan, Editor, in the May/June 2013 edition of sp2 Inter-Active. The article explores the origins of BioMoti, it’s technological capabilities, lead ovarian cancer candidate, business model, growth plans and the current context for early stage UK biotech companies.

Click for article: BioMoti sp2 MayJune 2013

Click here to read the May/June 2013 issue of sp2 Inter-Active